Passage Bio, Inc. (PASG)
| Market Cap | 1.29B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 45.50M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $28.24 |
| Previous Close | $29.83 |
| Change ($) | -1.59 |
| Change (%) | -5.33% |
| Day's Open | 29.91 |
| Day's Range | 27.67 - 29.95 |
| Day's Volume | 186,499 |
| 52-Week Range | 8.86 - 36.07 |
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice Presid...
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021
- Company invests to build in-house capabilities to support advancement of pipeline -
- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -
- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical tria...
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent fiel...
PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript
– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expect...
Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients
PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
About PASG
Passage Bio, a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
| Industry Biotechnology | IPO Date Feb 28, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol PASG |
Analyst Forecasts
According to 5 analysts, the average rating for Passage Bio stock is "Buy." The 12-month stock price forecast is 29.13, which is an increase of 3.15% from the latest price.